Bosh sahifaORX • STO
add
Orexo AB
Yopilish kursi
15,48 kr
Kunlik diapazon
15,00 kr - 15,64 kr
Yillik diapazon
9,18 kr - 24,00 kr
Bozor kapitalizatsiyasi
537,32 mln SEK
Oʻrtacha hajm
15,11 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
STO
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 146,20 mln | 4,95% |
Joriy xarajat | 124,70 mln | -7,36% |
Sof foyda | -15,90 mln | -78,65% |
Sof foyda marjasi | -10,88 | -70,27% |
Har bir ulushga tushum | -0,46 | -76,92% |
EBITDA | 11,90 mln | -0,83% |
Amaldagi soliq stavkasi | 17,19% | — |
Balans
Jami aktivlari
Jami passivlari
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 119,10 mln | -39,85% |
Jami aktivlari | 529,00 mln | -36,26% |
Jami passivlari | 690,30 mln | -10,18% |
Umumiy kapital | -161,30 mln | — |
Tarqatilgan aksiyalar | 34,51 mln | — |
Narxi/balansdagi bahosi | -3,31 | — |
Aktivlardan daromad | 0,36% | — |
Kapitaldan daromad | 0,59% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -15,90 mln | -78,65% |
Operatsiyalardan naqd pul | 32,90 mln | 274,07% |
Sarmoyadan naqd pul | -19,20 mln | -1 500,00% |
Moliyadan naqd pul | -7,00 mln | -116,17% |
Naqd pulning sof oʻzgarishi | -4,10 mln | -115,19% |
Boʻsh pul | 56,31 mln | 307,89% |
Haqida
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
Tashkil etilgan
1995
Sayt
Xodimlar soni
110
